Brooklyn Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brooklyn Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$765K	Buy	13,536 +6,108	+82%	+$356K	0.02%	715
2025 Q4	$446K	Buy	+7,428	New	+$404K	0.02%	751
2025 Q3	–	Sell	-1,345	Closed	-$73.9K	–	929
2025 Q2	$73.9K	Buy	1,345 +781	+138%	+$46K	0.01%	1120
2025 Q1	$39.9K	Buy	564 +540	+2,250%	+$36.3K	0.01%	882
2024 Q4	$1.58K	Sell	24 -218	-90%	-$14.6K	﹤0.01%	1525
2024 Q3	$17K	Buy	+242	New	+$20.2K	0.01%	685

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brooklyn Investment Group's BMRN Position: Q1 2026 in Review

Brooklyn Investment Group increased its BioMarin Pharmaceuticals (BMRN) stake by 82% in Q1 2026, buying an estimated $356K and bringing the position to 13,536 shares worth $765K. The position accounts for 0.02% of the portfolio, ranked #715.

Brooklyn Investment Group first reported a position in BMRN in Q3 2024 and has held it in 6 quarters since. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Brooklyn Investment Group held 13,536 shares of BioMarin Pharmaceuticals worth $765K as of Q1 2026.
Brooklyn Investment Group bought 6,108 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $356K.
BioMarin Pharmaceuticals made up 0.02% of Brooklyn Investment Group's portfolio in Q1 2026, its #715 holding.
Brooklyn Investment Group first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.